![](/img/cover-not-exists.png)
PRO38 COST-EFFECTIVENESS ANALYSIS OF EMICIZUMAB VERSUS BYPASSING AGENTS IN PATIENTS WITH HEMOPHILIA A WITH INHIBITORS IN THE BRAZILIAN PUBLIC HEALTHCARE SYSTEM PERSPECTIVE
Souza, P., Puopolo, G.R., Leme-Souza, R.Volume:
22
Language:
english
Journal:
Value in Health
DOI:
10.1016/j.jval.2019.09.2368
Date:
November, 2019
File:
PDF, 387 KB
english, 2019